Partially hydrolyzed guar gum characterization and sensitive quantification in food matrices by high performance anion exchange chromatography with pulsed amperometric detection—Validation using accuracy profile

Determination of carrageenan and konjac gum in livestock meat and meat products by ultra performance liquid chromatography-tandem mass spectrometry

At present, gum-injected meat appeared in the market, which has seriously damaged the legitimate rights and interests of consumers. Therefore, a method for the determination of carrageenan and konjac gum in livestock meat and meat products by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was established. The samples were hydrolyzed by hydrogen nitrate. After centrifugation and dilution, the supernatants were detected by the UPLC-MS/MS and the concentration of target compounds in samples were calibrated by the matrix calibration curves. A good linear relationship was observed in the concentration range of 5-100 μg/mL with correlation coefficients of more than 0.995. The limits of detection (LODs) and limits of quantification (LOQs) were found to be 20 and 50 mg/kg, respectively. The recoveries at three spiked levels (50, 100 and 500 mg/kg) in blank matrix were in the range of 84.8-108.6% with the relative standard deviations between 1.5% and 6.4%. The method has the advantages of convenient, accurate and efficient, and can be used as an effective method for detecting carrageenan and konjac gum in the different kinds of livestock meat and meat products.

Bacterial, short-chain fatty acid and gas profiles of partially hydrolyzed guar gum in vitro fermentation by human fecal microbiota

Carbohydrates with different structures have metabolic differences in the human body, as well as individual differences. The present study aimed to investigate the effects of bacterial, short-chain fatty acids (SCFAs) and gas profiles of partially hydrolyzed guar gum (PHGG) on the fecal microbiota of 41 Chinese individuals by simulated fermentation in vitro. Results showed that PHGG stimulated the growth of Bifidobacterium and Faecalibacterium, inhibited the growth of Escherichia-Shigella, Klebsiella, and Dorea, and induced the production of fermentation gases (CO2, and H2) and SCFAs (acetic acid, butyric acid). Furthermore, Bifidobacterium was significantly increased in the young female and the old male-originated samples, while Klebsiella was significantly decreased in the old female ones after PHGG intervention, and there were also certain differences in gases and SCFAs among different population samples. These findings indicate that PHGG can modulate gut microbiota and metabolism well, whereas its use varies in different populations.

Shaping the Future of Probiotics and Prebiotics

Recent and ongoing developments in microbiome science are enabling new frontiers of research for probiotics and prebiotics. Novel types, mechanisms, and applications currently under study have the potential to change scientific understanding as well as nutritional and healthcare applications of these interventions. The expansion of related fields of microbiome-targeted interventions, and an evolving landscape for implementation across regulatory, policy, prescriber, and consumer spheres, portends an era of significant change. In this review we examine recent, emerging, and anticipated trends in probiotic and prebiotic science, and create a vision for broad areas of developing influence in the field.

Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection

Generally, tyrosine kinase inhibitors have narrow therapeutic window and large interpatient variability compared to intrapatient variability. In order to support its therapeutic drug monitoring, two fast and accurate methods were developed for the determination of recently FDA approved anticancer tyrosine kinase inhibitors, afatinib and ibrutinib, in human plasma using ultra high performance liquid chromatography coupled to PDA detection. Diclofenac sodium was used as internal standard. The chromatographic separation was achieved on an Acquity UPLC BEH C18 analytical column using a mobile phase combining ammonium formate buffer and acetonitrile at a constant flow rate of 0.4 mL/min using gradient elution mode. A µSPE (solid phase extraction) procedure, using Oasis MCX µElution plates, was processed and it gave satisfying and reproducible results in terms of extraction yields. Additionally, the methods were successfully validated using the accuracy profiles approach (β = 95% and acceptance limits = ±15%) over the ranges 5-250 ng/mL for afatinib and from 5 to 400 ng/mL for ibrutinib in human plasma.